CNS Pharmaceuticals reports Q3 net loss of $3.3 million
I'm PortAI, I can summarize articles.
CNS Pharmaceuticals reported a Q3 2025 net loss of $3.3 million, an improvement from a $5.6 million loss in Q3 2024. Research and development expenses decreased to $2.2 million, and general and administrative expenses fell to $1.1 million. The company expects its cash to fund operations into the second half of 2026 and is advancing its TPI 287 program for glioblastoma multiforme, with plans to engage the FDA in early 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments